We use analytics cookies to give us insight into how our website is being used. Learn more in our cookie notice I Accept +

+44 (0) 20 3997 7634 | sales@fbkmed.com

  • Feedback Medical
  • About

    About

    • About Us
    • History
    • Team
  • Products

    Products

    • TexRAD
      • TexRAD Research
        • Resources
      • TexRAD Publications
    • Cadran
      • Cadran Pacs
    • Bleepa®
      • About Bleepa
      • Bleepa Case Studies
      • Bleepa FAQ
      • Request A Bleepa Demo
  • Insights

    Insights

    • Testimonials
    • Publications
  • News
  • Careers
  • Contact
  • Investor Relations - Feedback PLC

    Feedback PLC

    • Feedback plc Homepage
    • About Feedback plc
    • Feedback PLC Team
    • Reports And Presentations
    • Announcements
    • Share Price
    • Governance
    • Shareholder Information
    • Advisors
    • AIM Rule 26
    • Contact Us

Adapting, evolving, enhancing Bleepa

Home > new features

Thank you to everyone who visited us at #ReWired23! We had a great show. @DHRewired

Feedback Medical Ltd
201 Temple Chambers,
3-7 Temple Avenue,
London
EC4Y 0DT

+44 (0) 20 3997 7634

sales@fbkmed.com

Cadran, TexRAD® and Bleepa® are all products by Feedback Medical Ltd. Feedback Medical Ltd is a company registered in England and Wales - Registered Number: 04025026 - Registered Office: 201 Temple Chambers, 3-7 Temple Avenue, London EC4Y 0DT

VAT number: GB760001191

© 2023 Feedback plc - Design and Development by MOBIUS MEDIA

Terms & Conditions Cookies Privacy Policy

  • Feedback Medical
    • About Us
    • History
    • Team
    • TexRAD
      • TexRAD Research
      • TexRAD Publications
    • Cadran
      • Cadran Pacs
    • Bleepa
      • About Bleepa
      • Bleepa Case Studies
      • Bleepa FAQ
      • Request A Bleepa Demo
    • Testimonials
    • Publications
  • News
  • Careers
  • Contact
    • Feedback plc Homepage
    • About Feedback plc
    • Feedback PLC Team
    • Reports And Presentations
    • Announcements
    • Share Price
    • Governance
    • Shareholder Information
    • Advisors
    • AIM Rule 26
    • Contact Us